Findings Demonstrate Lycera’s Compound Selectively Silences Pathogenic Cells and Arrests Graft-Versus-Host Disease PLYMOUTH, Mich. – January 26, 2011 – Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced positive data from the University of Michigan demonstrating the role of bioenergetics in selectively inhibiting pathogenic… Read More

Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft versus host disease… Read More

Characterization of the metabolic phenotype of chronically activated lymphocytes… Read More

Significant Progress Made in Advancing Company’s Small Molecules for the Treatment of Autoimmune Diseases; Appoints Chairman of the Board and Welcomes New Vice President in Preparation for Clinic Ann Arbor, Mich., and Cambridge, Mass. – April 28, 2010 — Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat… Read More

Former Head of U.S. Commercial at Biogen Idec Will Lead Emerging Small Molecule Immunology Company in Next Phase of Growth Ann Arbor, Mich., and Cambridge, Mass. – January 7, 2010 — Lycera Corporation, a pharmaceutical company focused on developing novel small-molecule medicines to treat autoimmune diseases, today announced that William J. Sibold has been named… Read More

ANN ARBOR, Mich., October 9, 2009 — Lycera Corp., which is developing novel small-molecule pharmaceuticals to treat autoimmune diseases, today announced the appointments of Paul S. Changelian, Ph.D. and Peter L. Toogood, Ph.D. to the company’s drug development team. Dr. Changelian, previously director of inflammation biology at Pfizer, will serve as vice president of biology.… Read More

ANN ARBOR, Mich., August, 18 2009 — Lycera Corp. today announced the appointment of five accomplished scientists and clinicians to its Scientific Advisory Board. The company, which recently announced a $36 million Series A financing, is developing novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. “Each of these… Read More

ANN ARBOR, Mich., July 29, 2009 —Lycera Corp. today announced that Robert Kamen, Ph.D., biotech consultant and past president of Abbott Bioresearch Center will join the company’s Board of Directors. Lycera, which recently announced a $36 million Series A financing, is developing novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory… Read More